Meta’s attempted acquisition of Manus has become the most useful case study in cross-border investment screening you’ll read this year. Not because of the deal itself, but because of what killed it.
Manus - an AI agent company with Chinese roots, re-headquartered in Singapore - was acquired by a US tech giant. On paper, that might once have looked like a clean transaction. In today’s market, it has been pulled into the gravitational field of two superpowers.
For compliance teams, though, the signs become far more problematic. The assumption was that a Singapore incorporation, US venture capital on the cap table, and a global acquirer would be enough to move the transaction out of China's regulatory orbit. It wasn't.
The regulatory perimeter around sensitive industries, particularly in technology, is widening - and fast.
The compliance problem in plain sight
China’s National Development and Reform Commission requires the parties to withdraw from the acquisition of Manus, an AI Agent business with Chinese origins incorporated in Singapore. The “Singapore washing” structure - relocating headquarters to reduce geopolitical friction - didn’t insulate the deal from Chinese regulatory reach. Regulators looked through the corporate structure, its origins, and the strategic relevance of the business.
That is the part compliance teams will focus on, because the same logic can apply to smaller portfolio holdings, not just major acquisitions.
If regulators are willing to assert control over a Singapore-incorporated company on the basis of its Chinese technological origins and AI capabilities, the question for any compliance function monitoring a portfolio with exposure to similar companies is: do we actually know where our holdings sit in the eyes of two competing regulatory systems?
Why existing frameworks are not enough anymore
Most compliance monitoring is predicated on what a company looks like on paper - jurisdiction of incorporation, ownership structure, industry classification. The Meta-Manus case is a reminder that regulators are looking beyond surface-level markers.
In this instance, two regulatory forces are converging for a perfect storm:
- Sensitive Industries regimes are expanding their reach, and the thresholds are small. This is reflected in Italy, where Golden Power rules can apply to holdings as low as 3% in listed companies operating in defence and national security.
- US outbound investment rules, colloquially known as “Reverse CFIUS”, restrict capital flows from US persons into Chinese AI, quantum, and semiconductor companies. For firms with US connections investing in companies that potentially have Chinese technological origins, that exposure may already exist in their portfolios and simply might not be visible.
The Manus situation is striking exactly because the company seemed fine on paper. Singapore incorporated. US venture capital backed. And a buyer with global reach. It still wasn’t enough to keep it out of China’s oversight.
Why it matters
The compliance challenge here is not about filing the right form or monitoring the right threshold. It is about knowing, in advance and continuously, where holdings sit relative to shifting regulatory boundaries. These shifts are taking place across jurisdictions, in real time, and often without clear notice. Jurisdiction of incorporation may no longer be a reliable proxy for regulatory exposure.
A few years ago, this kind of acquisition might have looked ambitious but not extraordinary. Today, AI, quantum, semiconductors and other strategic technologies sit at the centre of national security, industrial, and capital markets policy simultaneously. The convergence has blurred the lines of what needs to be monitored.
That is the real story. The two companies are stuck in the middle, with commercial value on one side and regulatory reaction on the other:
- China is asserting control over technology with Chinese origins.
- The US is tightening its view of capital flowing into sensitive foreign technology.
- Investors and acquirers are left trying to produce value while two regulatory systems pull in opposite directions.
A Singapore incorporation and US venture capital on the cap table used to be enough. A global acquirer on the other side helped. These were the signals that told compliance teams a transaction was clean. Regulators are now looking through all of it - founders, assets, technology, data, funding history and strategic relevance - and the old proxies are not holding.
The better question to ask, much earlier: does the founding history, technology type, or sector exposure of this target create a regulatory surface area we haven't mapped yet? If your current process doesn't have a clean answer to that before the first term sheet, that's the gap worth closing.
The lesson from Meta and Manus is simple. Cross border investment screening is a front line strategic issue, not a back-end compliance check. The firms that treat it that way will be the ones that aren’t surprised.
